Cargando…

The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study

Therapeutic options are limited in relapsed/refractory acute myeloid leukemia (AML). We evaluated the maximum tolerated dose (MTD) and preliminary efficacy of mammalian target of rapamycin (mTOR) inhibitor, everolimus (days 5–21) in combination with azacitidine 75 mg/m(2) subcutaneously (days 1–5 an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Peter, Tiong, Ing Soo, Fleming, Shaun, Pomilio, Giovanna, Cummings, Nik, Droogleever, Mark, McManus, Julie, Schwarer, Anthony, Catalano, John, Patil, Sushrut, Avery, Sharon, Spencer, Andrew, Wei, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581027/ https://www.ncbi.nlm.nih.gov/pubmed/28881728 http://dx.doi.org/10.18632/oncotarget.13699

Ejemplares similares

Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors
por: Yim, Kein-Leong
Publicado: (2012)

Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma
por: Kiessling, Michael K., et al.
Publicado: (2016)

mTOR inhibitor Everolimus-induced apoptosis in melanoma cells
por: Ciołczyk-Wierzbicka, Dorota, et al.
Publicado: (2019)

mTOR inhibitor everolimus reduces invasiveness of melanoma cells
por: Ciołczyk-Wierzbicka, Dorota, et al.
Publicado: (2019)

A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
por: Wise-Draper, Trisha M., et al.
Publicado: (2017)

Correction: Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma
por: Kiessling, Michael K., et al.
Publicado: (2017)

Experience with the mTOR Inhibitor Everolimus in Pediatric Liver Graft Recipients
por: Wehming, Mathis, et al.
Publicado: (2023)

Investigation of the effects of mTOR inhibitors rapamycin and everolimus in combination with carboplatin on canine malignant melanoma cells
por: Bernard, Sarah, et al.
Publicado: (2021)

A phase Ib study of everolimus combined with metformin for patients with advanced cancer
por: Molenaar, Remco J., et al.
Publicado: (2017)

Repurposing Verapamil to Enhance Killing of T-ALL Cells by the mTOR Inhibitor Everolimus
por: Silic-Benussi, Micol, et al.
Publicado: (2023)

DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells
por: Mangili, Federica, et al.
Publicado: (2022)

Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models
por: Kuo, Chun-Ting, et al.
Publicado: (2019)

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
por: Campone, M, et al.
Publicado: (2009)

Favorable outcomes of DDX41‐mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomide
por: Tiong, Ing S., et al.
Publicado: (2023)

Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome
por: Tan, P, et al.
Publicado: (2014)

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
por: Witzig, T E, et al.
Publicado: (2011)

Successful treatment with the mTOR inhibitor everolimus in a patient with Perivascular epithelioid cell tumor
por: Gennatas, Constantine, et al.
Publicado: (2012)

Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells
por: Justin, Saira, et al.
Publicado: (2020)

Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells
por: El Guerrab, Abderrahim, et al.
Publicado: (2020)

[Retracted] Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells
por: Taglieri, Ludovica, et al.
Publicado: (2023)

PMON171 DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Pituitary Neuroendocrine Tumoral Cells
por: Mangili, Federica, et al.
Publicado: (2022)

Author Correction: Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models
por: Kuo, Chun-Ting, et al.
Publicado: (2020)

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results
por: Daver, Naval G., et al.
Publicado: (2023)

Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma
por: Hirashima, K, et al.
Publicado: (2012)

Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma
por: Li, Siming, et al.
Publicado: (2014)

mTOR Inhibition by Everolimus in Childhood Acute Lymphoblastic Leukemia Induces Caspase-Independent Cell Death
por: Baraz, Rana, et al.
Publicado: (2014)

Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer
por: Kordes, S., et al.
Publicado: (2015)

mTOR Inhibition by Everolimus Does Not Impair Closure of Punch Biopsy Wounds in Renal Transplant Patients
por: Dutt, Shelley B., et al.
Publicado: (2017)

mTOR Pathway Expression as Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus
por: Gelsomino, Fabio, et al.
Publicado: (2020)

Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model
por: Ramsey, Haley E., et al.
Publicado: (2020)

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies
por: Deenen, Maarten J., et al.
Publicado: (2011)

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo
por: Cejka, D, et al.
Publicado: (2009)

Protective Effects of the mTOR Inhibitor Everolimus on Cytoskeletal Injury in Human Podocytes Are Mediated by RhoA Signaling
por: Jeruschke, Stefanie, et al.
Publicado: (2013)

Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy
por: Wheless, James W.
Publicado: (2015)

Nanosecond Pulsed Electric Fields Enhance the Anti-tumour Effects of the mTOR Inhibitor Everolimus against Melanoma
por: Dai, Jie, et al.
Publicado: (2017)

Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma
por: Negri, Mariarosaria, et al.
Publicado: (2022)

ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer
por: Farmaki, Elena, et al.
Publicado: (2023)

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
por: Bianco, R, et al.
Publicado: (2008)

Incidence and Risk of Treatment-Related Mortality with mTOR Inhibitors Everolimus and Temsirolimus in Cancer Patients: A Meta-Analysis
por: Qi, Wei-Xiang, et al.
Publicado: (2013)

Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway
por: Du, Liyan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_44vto03kda7irgojik9n55cp11